RLAY
Relay Therapeutics, Inc.
Key Financials
Operating Income
$-302738000
↑ 18.7%
Net Income
$-276479000
↑ 18.1%
EPS (Diluted)
$-1.61
↑ 31.8%
Revenue
$15.4M
↑ 53.4%
Cash & Equivalents
$84.0M
↓ 32.4%
Shareholders' Equity
$567.1M
↓ 27.1%
Total Liabilities
$54.3M
↓ 42.0%
Total Assets
$621.3M
↓ 28.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 424B5 | 5/19/2026 | View on SEC |
| 8-K | 5/19/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 4 | 5/14/2026 | View on SEC |
| 144 | 5/14/2026 | View on SEC |
| 10-Q | 5/5/2026 | View on SEC |
| 8-K | 5/5/2026 | View on SEC |
| 4 | 4/30/2026 | View on SEC |
| 4 | 4/30/2026 | View on SEC |
| 4 | 4/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RLAY |
| Company Name | Relay Therapeutics, Inc. |
| CIK | 1812364 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-370-8837 |